Fenwick Represents Formation Bio in $372M Series D Funding

Fenwick represented Formation Bio, a tech-driven and AI-native pharma company, in its $372 million Series D funding. The round was led by a16z with significant participation from Sanofi. Current investors also joined the round, including Sequoia, Thrive, Emerson Collective, and Lachy Groom, along with new investors, such as SV Angel Growth and FPV Ventures.

Formation Bio will use the funds for acquiring and in-licensing candidate drugs and expanding their AI capabilities. More information can be obtained from the company’s announcement.

The Fenwick transaction team was led by corporate partners Michael Esquivel and Will Black and included associates Tracy Kennberg, Grace Fernandez, Shannon Lieu, Kaylee Johnson, and Jazmin Perez; and Life Sciences and Health Tech partner Stefano Quintini.